Business
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets
About this update from Vyome Holdings, Inc.
[{"type":"text","content":"\nLaunches business unit to create AI psychiatrist focused on reducing inflammation\n\n\nVyome remains fully funded through 2026 to unlock value from core assets\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nVyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology (“MIT”). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo’s assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of Krishna Gupta, Mohanjit Jolly, and Stash Pomichter – all of whom are MIT alumni with deep AI expertise.\n\n\n“Inflammation is currently one of the biggest health crises facing humanity, and we intend to attack the condition from all angles in order to limit the usage of steroids,” said Stash Pomichter, a Director of Vyome. “We envision an AI psychiatrist that can diagnose and help treat systemic inflammation by targeting behavioral drivers and biomarkers.”\n\n\n“The goal is to establish an entirely new therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health, with global commercialization beginning in the US and India. The team at Oculo has developed an innovative foundation of software and research, including on biomarkers such as ‘brain burn’ that are quite relevant to our focus at Vyome, and we are excited to build on this foundation,” added Pomichter.\n\n\nThe Oculo transaction will have no bearing on the progress of Vyome’s core biotech assets. Vyome remains funded through 2026 to progress its core business.\n\n\n“We launched Oculo to build at the intersection of the human body and the human mind, and to quantify the workings of the mind by taking advantage of the latest advances in AI,” said Alay Shah, founder of Oculo. “I’ve always believed the best AI products would be built firmly with humans in the loop and I’m excited Vyome will carry forth this vision as they target inflammation.”\n\n\n“The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could en...